Therapeutic solutions to hinder the effects of sickle hemoglobin (HbS) polymerization are
highly sought after. Measuring the kinetics of polymerization of HbS using laser photolysis …

The dominant assumption central to most treatments for sickle cell anemia has been that
replacement of sickle hemoglobin (HbS) by fetal hemoglobin (HbF) would have major …

Sickle Cell Disease results from a point mutation on the beta subgroups of hemoglobin.
When hemoglobin releases its four ligands it changes from a relaxed (R) structure to a tense …

Although hundreds of different hemoglobin variants have now been identified,
polymerization seems to be a unique property of HbS. 1 Polymerization has been …

Recent interest in therapies for sickle cell anemia based on elevating fetal Hb has made
accurate estimates of the sparing effect of fetal Hb (Hb F) and other non-sickle Hbs on sickle …

This chapter surveys the molecular events that cause individual hemoglobin tetramers to
become a stiff polymer mass with devastating consequences. It outlines the principles of …

Background: Sickle cell disease (SCD) is caused by polymerization of sickle hemoglobin
(HbS), resulting in red blood cell (RBC) sickling, RBC destruction, vaso-occlusion and end …

Sickle hemoglobin (HbS) is a point mutation of the two β subunits in normal Hb (HbA) that
leads to nucleated polymerization and accompanying pathology. We measured the rates of …

Although it has been known for more than 60 years that the cause of sickle cell disease is
polymerization of a hemoglobin mutant, hydroxyurea is the only drug approved for treatment …

In sickle hemoglobin (HbS), a valine is substituted for glutamic acid in the sixth codon of the
globin chain. This change endows deoxyHbS, but not oxyHbS, with a new property: the …